

**IN THE CLAIMS**

Please amend the claims as follows:

Claims 1-27 (canceled)

Claim 28 (currently amended): A method for improving prognosis, neurological symptoms, or motor dysfunction of a disease resulting from cerebral infarction, comprising:  
intravenously administering an effective amount of paraoxonase to improve one of prognosis, neurological symptoms and motor dysfunction of a disease resulting from cerebral infarction to a patient in need thereof.

Claim 29 (currently amended): The method of claim 28, wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering an effective amount of 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in combination.

Claim 30 (currently amended): The method of claim 28, wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering the effective amount of paraoxonase in the presence of a polyol.

Claim 31 (currently amended): The method of claim 28, wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering the effective amount of paraoxonase in the presence of a glycerol.

Claims 32-34 (canceled)

Claim 35 (previously presented): The method of claim 28, wherein the paraoxonase is a purified paraoxonase.

Claim 36 (previously presented): The method of claim 28, wherein the paraoxonase is a purified paraoxonase having a specific activity in a range of 100 to 2000 U/A<sub>280</sub>.

Claim 37 (previously presented): The method of claim 28, wherein the paraoxonase is a purified paraoxonase having a specific activity in a range of 500 to 1800 U/A<sub>280</sub>.

Claim 38 (currently amended): The method of claim 28, wherein the intravenously administering of the effective amount of paraoxonase comprises intravenously administering an effective amount of a detergent to stabilize an activity of the paraoxonase in combination.

Claim 39 (new): A method for improving prognosis, neurological symptoms, or motor dysfunction of a disease resulting from cerebral infarction, comprising:

intravenously administering an effective amount of paraoxonase once daily for 1 to 14 days to improve one of prognosis, neurological symptoms and motor dysfunction of a disease resulting from cerebral infarction to a patient in need thereof,

wherein the intravenous administering of paraoxonase is started within 48 hours after onset of a disease resulting from cerebral infarction.

Claim 40 (new): The method of claim 39, wherein paraoxonase is administered intravenously once daily for 1 to 7 days.

Claim 41 (new): The method of claim 40, wherein paraoxonase is administered intravenously within 24 hours after onset of a disease resulting from cerebral infarction.

Claim 42 (new): The method of claim 40, wherein paraoxonase is administered intravenously within 12 hours after onset of a disease resulting from cerebral infarction.

Claim 43 (new): The method of claim 40, wherein paraoxonase is administered intravenously within 3 hours after onset of a disease resulting from cerebral infarction.